LeonaBio (LONA) Income from Continuing Operations (2019 - 2026)
LeonaBio's (LONA) quarterly Income from Continuing Operations came in at 21108000.0 in Q1 2026, down 96.12% year-on-year from 543505751.2 in Q1 2025, and up 73.81% on a QoQ basis from 80595000.0 in Q4 2025.
LeonaBio (LONA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has 8 years of Income from Continuing Operations data on file, last reported at 21108000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 96.12% year-over-year to 21108000.0 in Q1 2026; TTM through Mar 2026 was 117954000.0, a 33.75% increase from a year earlier, with the FY2025 full-year figure at 105610000.0, down 8.98% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 21108000.0, up from 80595000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LONA reached as high as 7855000.0 in Q3 2025 and fell as low as 107515000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 33835588.24 across 5 years, with a median of 29401000.0 in 2023.
- Across the five-year window, Income from Continuing Operations slumped 265.68% in 2024 and soared 74.74% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 33323000.0 in 2022, then rose by 11.77% to 29401000.0 in 2023, then slumped by 265.68% to 107515000.0 in 2024, then increased by 25.04% to 80595000.0 in 2025, then soared by 73.81% to 21108000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 21108000.0 in Q1 2026, 80595000.0 in Q4 2025, and 7855000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | LeonaBio | 138.33 Mn | 70.65 Mn | - | -21.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.11 Mn |
| Dec 31, 2025 | -80.60 Mn |
| Sep 30, 2025 | -7.86 Mn |
| Jun 30, 2025 | -8.40 Mn |
| Mar 31, 2025 | -10.76 Mn |
| Dec 31, 2024 | -107.52 Mn |
| Sep 30, 2024 | -31.09 Mn |
| Jun 30, 2024 | -28.68 Mn |
| Mar 31, 2024 | -29.40 Mn |
| Dec 31, 2023 | -29.40 Mn |
| Sep 30, 2023 | -36.99 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -31.95 Mn |
| Dec 31, 2022 | -33.32 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -24.36 Mn |
| Mar 31, 2022 | -33.52 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -23.83 Mn |
| Jun 30, 2021 | -24.34 Mn |